Blog
About

15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.

      , ,

      Folia medica

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This article's objective is to critically assess the Bulgarian legislation on health technology assessment (HTA). It analyses how innovative therapies and orphan drugs in particular would respond to the regulators' decision-making criteria for reimbursement.

          Related collections

          Author and article information

          Journal
          Folia Med (Plovdiv)
          Folia medica
          0204-8043
          0204-8043
          : 55
          : 3-4
          Article
          24712287

          Comments

          Comment on this article